Health Care & Life Sciences » Pharmaceuticals | RaQualia Pharma Inc.

RaQualia Pharma Inc. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
1,102,158.00
631,699.00
1,848,460.00
722,705.00
59,848.00
Depreciation, Depletion & Amortization
68,155.00
21,272.00
53,353.00
79,877.00
85,785.00
Other Funds
1,132,944.00
1,528,251.00
99,378.00
32,667.00
55,974.00
Funds from Operations
2,166,947.00
2,138,678.00
1,894,485.00
675,495.00
30,038.00
Changes in Working Capital
12,268.00
57,652.00
222,048.00
5,444.00
277,396.00
Net Operating Cash Flow
2,179,215.00
2,081,026.00
2,116,533.00
680,939.00
307,434.00
Capital Expenditures
26,107.00
101,106.00
199,526.00
37,184.00
88,449.00
Sale of Fixed Assets & Businesses
3,922.00
1,943.00
-
-
-
Purchase/Sale of Investments
969,244.00
693,025.00
869,644.00
404,234.00
622,510.00
Net Investing Cash Flow
951,847.00
796,123.00
665,915.00
441,418.00
533,800.00
Issuance/Reduction of Debt, Net
-
140,000.00
-
-
-
Net Financing Cash Flow
309,275.00
761,766.00
1,701,710.00
-
1,007,321.00
Net Change in Cash
854,760.00
2,030,933.00
251,718.00
1,155,918.00
1,229,427.00
Free Cash Flow
2,192,390.00
2,177,828.00
2,312,078.00
716,788.00
394,943.00
Other Sources
69,427.00
-
-
-
-
Change in Capital Stock
309,275.00
621,766.00
1,701,710.00
-
1,007,321.00
Exchange Rate Effect
63,333.00
84,450.00
626.00
33,561.00
4,260.00
Other Uses
64,639.00
3,935.00
4,203.00
-
259.00

About RaQualia Pharma

View Profile
Address
Daiwa Meieki Building, 8/F
Nagoya Aichi 450
Japan
Employees -
Website http://www.raqualia.co.jp
Updated 09/14/2018
RaQualia Pharma, Inc. engages in a research and development of pharmaceuticals. Its medicines focus on pain, gastrointestinal, auto-immune diseases, inflammation, cancer, and Alzheimer's. Its products include Anidulafungin, Dalbavancin, Ziprasidone, 5-HT4 Partial Agonist, and 5-HT2B Antagonist.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.